Pulmatrix Inc
(NASDAQ : PULM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.95%176.301.2%$600.82m
GILDGilead Sciences, Inc.
0.62%68.020.9%$542.46m
BIIBBiogen Inc.
-0.06%280.401.2%$519.30m
CELGCelgene Corporation
-2.01%78.371.2%$513.71m
REGNRegeneron Pharmaceuticals, Inc.
-2.01%301.812.6%$316.79m
ALXNAlexion Pharmaceuticals, Inc.
-0.07%121.072.0%$253.26m
ILMNIllumina, Inc.
0.45%269.673.5%$244.32m
VRTXVertex Pharmaceuticals Incorporated
0.58%157.241.9%$236.54m
NKTRNektar Therapeutics
7.66%85.306.0%$212.18m
AAgilent Technologies, Inc.
1.15%64.321.5%$199.05m
INCYIncyte Corporation
1.79%67.832.5%$194.51m
SRPTSarepta Therapeutics, Inc.
1.78%93.4816.6%$131.29m
EXASExact Sciences Corporation
2.43%52.3625.5%$116.06m
BMRNBioMarin Pharmaceutical Inc.
0.51%88.884.4%$114.43m
ALNYAlnylam Pharmaceuticals, Inc
1.15%102.819.8%$103.66m

Company Profile

Pulmatrix, Inc. is a clinical stage biotechnology company, which is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. It designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Edwards, Mark Gabrielson, Alexander Klibanov, and Robert Langer in 2013 and is headquartered in Lexington, MA.